BiotechTube
Baseimmune

Baseimmune

Oxford, United Kingdom· Est.
baseimmune.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11M

Overview

Baseimmune is an Oxford, UK-based biotech developing AI-designed vaccines and immunotherapies for chronic diseases. The company's core technology is a computational platform that creates novel, bespoke antigens intended to overcome the limitations of traditional vaccine approaches. Founded in 2019, it is a private, venture-backed company in the pre-clinical stage. Its leadership includes a mix of experienced venture capitalists and a distinguished scientific advisory board with expertise in immunology and chronic disease.

Chronic Diseases

Technology Platform

Proprietary AI-driven computational platform that designs bespoke, multi-epitope vaccine antigens by analyzing genomic, epidemiological, and immunological data to predict pathogen evolution and optimize for broad, durable immune protection.

Funding History

1
Total raised:$11M
Seed$11M

Opportunities

The platform can be applied to a wide range of chronic diseases with high unmet need, such as persistent viral infections and fibrotic disorders, representing large and growing therapeutic markets.
Successfully validating the AI design approach could position the company as a leader in next-generation immunotherapy and attract lucrative platform partnerships with large pharmaceutical companies.

Risk Factors

The core technology is unproven, with high risk that computationally designed antigens may fail to demonstrate adequate efficacy or safety in pre-clinical and clinical testing.
As a pre-revenue company, it is dependent on volatile venture capital markets for funding to sustain its long, expensive R&D pathway.

Competitive Landscape

Baseimmune operates in the competitive and rapidly evolving field of computational vaccine design, facing competition from other AI-biotech startups (e.g., Osivax, Vaxxinity's approach) as well as internal initiatives at large vaccine developers (GSK, Pfizer, Moderna). Its differentiation hinges on the unique architecture of its AI platform and its specific focus on complex, chronic disease antigens.

More companies in United Kingdom →